GlassScriptPhysician profile
Sunil N Kadakia
NPI 1780763516
$4,547.76
in general payments reported to CMS, 2019-2025
30 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $149 · 2021: $95.71 · 2022: $1,017 · 2023: $988 · 2024: $1,111 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $613.35 | 2020-2025 | |
| Abiomed | $555.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.24 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $338.63 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $290.00 | 2020-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $235.56 | 2020-2024 | Xarelto |
| Abbott Laboratories | $229.01 | 2022-2025 | Cardiomems, Assurity, Gallant |
| Merck Sharp & Dohme LLC | $219.43 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $202.55 | 2021-2025 | Farxiga |
| Pfizer INC. | $172.72 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $142.10 | 2024-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $136.14 | 2024-2025 | |
| Chiesi USA, INC. | $113.07 | 2019 | |
| Boston Scientific Corporation | $112.37 | 2022-2025 | Rhythmia Mapping System |
| Medtronic, INC. | $110.11 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $106.55 | 2023-2024 | Edarbi, Edarbi |
| Lexicon Pharmaceuticals, INC. | $105.14 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $101.82 | 2019 | |
| Impulse Dynamics (USA) INC. | $68.07 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.84 | 2023-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $49.13 | 2023 | Uptravi, Opsumit |
| Amgen INC. | $45.39 | 2024 | Repatha |
| Scpharmaceuticals INC. | $39.23 | 2024 | |
| Inspire Medical Systems, INC. | $34.83 | 2023-2024 | Inspire |
| Edwards Lifesciences Corporation | $18.82 | 2022 | |
| Medicomp INC | $18.24 | 2024 | Telepatch Cardiac Monitor |
| Angiodynamics, INC. | $15.14 | 2022 | |
| Biotronik INC. | $13.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.55 | 2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.